Global Kidney (Renal) Fibrosis Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Kidney (Renal) Fibrosis Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Kidney fibrosis is characterized by excessive production and deposition of extracellular matrix (ECM) proteins mainly in the kidney interstitium and results in structural damage, impairment of renal function, and eventually end-stage renal disease (ESRD).
Kidney (Renal) Fibrosis report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Kidney (Renal) Fibrosis market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Research Center and Hospital are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Kidney (Renal) Fibrosis industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Kidney (Renal) Fibrosis key manufacturers include Merck, Pfizer, Roche, InterMune, Galectin Therapeutics, La Jolla Pharmaceutical Company, ProMetic Life-Sciences Inc., BioLine Rx Ltd and Genzyme Corporation, etc. Merck, Pfizer, Roche are top 3 players and held % sales share in total in 2022.
Kidney (Renal) Fibrosis can be divided into Angiotensin Converting enzyme (ACE) Inhibitors, Pirfenidone, Renin Inhibitors and Angiotensin II Receptor Blockers (ARBs), etc. Angiotensin Converting enzyme (ACE) Inhibitors is the mainstream product in the market, accounting for % sales share globally in 2022.
Kidney (Renal) Fibrosis is widely used in various fields, such as Research Center, Hospital and Clinic,, etc. Research Center provides greatest supports to the Kidney (Renal) Fibrosis industry development. In 2022, global % sales of Kidney (Renal) Fibrosis went into Research Center filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Kidney (Renal) Fibrosis market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Merck
Pfizer
Roche
InterMune
Galectin Therapeutics
La Jolla Pharmaceutical Company
ProMetic Life-Sciences Inc.
BioLine Rx Ltd
Genzyme Corporation
Segment by Type
Angiotensin Converting enzyme (ACE) Inhibitors
Pirfenidone
Renin Inhibitors
Angiotensin II Receptor Blockers (ARBs)
Vasopeptidase Inhibitors
Research Center
Hospital
Clinic
North America
the United States
Canada
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Kidney (Renal) Fibrosis market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Kidney (Renal) Fibrosis, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Kidney (Renal) Fibrosis industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Kidney (Renal) Fibrosis in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Kidney (Renal) Fibrosis introduction, etc. Kidney (Renal) Fibrosis Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Kidney (Renal) Fibrosis market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Kidney (Renal) Fibrosis report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Kidney (Renal) Fibrosis market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Research Center and Hospital are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Kidney (Renal) Fibrosis industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Kidney (Renal) Fibrosis key manufacturers include Merck, Pfizer, Roche, InterMune, Galectin Therapeutics, La Jolla Pharmaceutical Company, ProMetic Life-Sciences Inc., BioLine Rx Ltd and Genzyme Corporation, etc. Merck, Pfizer, Roche are top 3 players and held % sales share in total in 2022.
Kidney (Renal) Fibrosis can be divided into Angiotensin Converting enzyme (ACE) Inhibitors, Pirfenidone, Renin Inhibitors and Angiotensin II Receptor Blockers (ARBs), etc. Angiotensin Converting enzyme (ACE) Inhibitors is the mainstream product in the market, accounting for % sales share globally in 2022.
Kidney (Renal) Fibrosis is widely used in various fields, such as Research Center, Hospital and Clinic,, etc. Research Center provides greatest supports to the Kidney (Renal) Fibrosis industry development. In 2022, global % sales of Kidney (Renal) Fibrosis went into Research Center filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Kidney (Renal) Fibrosis market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Merck
Pfizer
Roche
InterMune
Galectin Therapeutics
La Jolla Pharmaceutical Company
ProMetic Life-Sciences Inc.
BioLine Rx Ltd
Genzyme Corporation
Segment by Type
Angiotensin Converting enzyme (ACE) Inhibitors
Pirfenidone
Renin Inhibitors
Angiotensin II Receptor Blockers (ARBs)
Vasopeptidase Inhibitors
Segment by Application
Research Center
Hospital
Clinic
Segment by Region
North America
the United States
Canada
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Kidney (Renal) Fibrosis market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Kidney (Renal) Fibrosis, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Kidney (Renal) Fibrosis industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Kidney (Renal) Fibrosis in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Kidney (Renal) Fibrosis introduction, etc. Kidney (Renal) Fibrosis Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Kidney (Renal) Fibrosis market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices